Nonetheless, the association between plasma EBV level, tumor PD-L1 expression, and outcomes with PD-1 inhibitors requires further characterization, as patients with higher pre-treatment EBV levels interestingly had a shorter median OS when treated with toripalimab, another PD-1 inhibitor (19). The gene discussed is PDCD1; the disease is neoplasm.